BioWound Solutions, a leader in innovative wound management based in Las Vegas, has announced an exclusive manufacturing agreement with Keraplast Limited, a pioneering biotechnology company from Christchurch, New Zealand. This partnership will see Keraplast manufacture BioWound’s advanced keratin-based wound care products—Keramatrix®, Keragel®, and Kerox®—for the US market.
The collaboration aims to provide clinicians and healthcare providers with cutting-edge therapies that accelerate healing and improve outcomes for patients with chronic wounds. Keraplast’s proprietary Replicine™ keratin technology, supported by decades of research and clinical evidence, is at the heart of these products, promoting cellular regeneration and natural wound closure while reducing scarring.
Nick Andolino, CEO of BioWound Solutions, described the partnership as a milestone that will help redefine standards of care for chronic wound patients. Howard Moore, CEO of Keraplast, highlighted the shared commitment to innovation and improving patient care.
This agreement supports BioWound Solutions’ mission to deliver high-quality, vertically integrated wound management products to healthcare providers and their patients.
To read the full press release click the link below.
